Novo Nordisk A/S (NVO) NYSE

68.93

-2.08(-2.93%)

Updated at July 11 04:00PM

Currency In USD

Novo Nordisk A/S

Address

Novo Alle 1

Bagsvaerd, 2880

Denmark

Phone

45 44 44 88 88

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

77406

First IPO Date

April 30, 1981

Key Executives

NameTitlePayYear Born
Mr. Lars Fruergaard JorgensenPresident, Chief Executive Officer & Member of Management Board4.86M1966
Dr. Martin Holst LangeExecutive Vice President of Development & Member of the Management Board1.84M1970
Dr. Marcus Schindler Ph.D.EVice President of Research & Early Development, Chief Scientific Officer & Member of the Management Board1.84M1966
Mr. Karsten Munk KnudsenExecutive Vice President, Chief Financial Officer & Member of the Management Board1.93M1971
Mr. Henrik Ehlers WulffExecutive Vice President of CMC & Product Supply and Member of the Management Board1.94M1970
Ms. Thilde Hummel BogebjergExecutive Vice President of Quality, IT & Environmental Affairs and Member of Management Board0N/A
Mr. Maziar Mike DoustdarExecutive Vice President of International Operations & Member of the Management Board01970
Mr. David S. MooreExecutive Vice President of US Operations & Member of Management Board01974
Ms. Tania SabroeEVice President of People, Organisation and Communication & Member of Management Board01977
Mr. Ludovic HelfgottExecutive Vice President of Product & Portfolio Strategy and Member of Management Board01974

Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.